• IN8bio presented updated survival results for its DeltEx DRI gamma-delta T cell therapy in newly diagnosed glioblastoma at ASCO 2026.
• Patients receiving repeat dosing with standard treatment showed longer disease control and survival than a contemporaneous standard-of-care comparison group.
• A meaningful share of treated patients remained alive at two years, outpacing the standard-of-care cohort.
• Safety profile remained supportive, with no major immune-related or neurologic safety signals reported in the studies.
• Immune and tissue analyses pointed to stronger anti-tumor immune activity, supporting a potential competitive differentiation in a long-stagnant treatment setting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IN8BIO Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606010830PRIMZONEFULLFEED9729313) on June 01, 2026, and is solely responsible for the information contained therein.